NEW YORK (GenomeWeb) – DiaGenomi and biotech consulting firm Healthcare Economics have formed a joint venture to bring DiaGenomi's pathology-assisted MyRisq genetic tests to the North American market, the companies said today.

DiaGenomi, which has offices in the UK and in Slovenia, offers a number of tests that combine DNA analysis with information about lifestyle, medical history, and blood tests to provide a report with a personalized risk assessment for conditions such as cardiovascular disease, sports injury, or multiple sclerosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.